'Small-molecule Cancer Drug Revenues Will Reach $32.7 Billion in 2016' Predicts New Visiongain Report

LONDON, January 8, 2013 /PRNewswire/ --

A new report by visiongain forecasts that small-molecule targeted cancer therapy revenues will reach $32.7bn worldwide in 2016. That drug market generated $21.7bn in 2011, according to Small-Molecule Targeted Cancer Therapies: World Market 2013-2023, published in December 2012. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2023. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate that drug market. The R&D pipeline holds great promise. Also, in most countries, high demand exists for newer, better cancer treatments. There remain many commercial opportunities for small-molecule cancer treatments from 2013 to 2023, the study concludes.

Targeted cancer therapies block the growth and spread of cancer by interfering with molecules involved in tumour (tumor) growth and progression. Unlike antibody therapies, small-molecule targeted cancer drugs pass through cell membranes to reach targets inside cells.

Dr Syed Ahmed, a senior healthcare industry analyst in visiongain, said: "There remains a high unmet medical need for drugs that not only prolong patients' survival but also significantly improve quality of life. Small-molecule targeted cancer agents will remain a prominent and lucrative part of the pharma market in the coming 10 years.

"The small-molecule targeted cancer therapy market continues to be dominated by blockbuster drugs led by Novartis' Glivec (Gleevec). Many of the products are due to lose patent protection during our forecast period, 2013-2023, leaving significant opportunities for producers of generic drugs (generics). However, a robust R&D pipeline for small-molecule cancer therapies will ensure this segment remains dynamic and promising for innovator companies."

Many small-molecule targeted technologies - including heat shock protein (HSP) modulators, HDAC mechanisms, transcription factor regulators and siRNA products - are in development for treating cancer. The R&D pipeline for those treatments is strong and vast, the report shows and discusses. Therapies are being studied for use alone, in combination with other targeted drugs, and combined with chemotherapy.

Much scope remains for medicines to combat growth, progression and spread of tumours. Visiongain's report shows revenue forecasts to 2023 at overall world market, product and national level. The investigation predicts revenues of leading drugs, including Glivec (Gleevec), Revlimid, Alimta, Velcade and Tarceva. Research, data and analyses cover activities of Novartis, Eli Lilly, Roche, Pfizer, Takeda and other pharmaceutical companies.

The new study discusses R&D and commercial developments, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 please visit http://www.visiongain.com/Report/948/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Companies Listed

4SC
AB Science
Abbott Laboratories
Abgenix
Abraxis BioScience
Acceleron
Acetylon Pharmaceuticals
ACT Biotech
Actavis
Active Biotech
Adeona (formerly Pipex)
AERES Biomedical
Aeterna Zentaris
Agennix
Alexion
Alza
Allos Therapeutics
Ambit Biosciences
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Amgen
AmpliMed
Anthrogenesis
Apexigen
Apotex
APP Pharmaceuticals (part of the Fresenius Kabi Group)
ARIAD Pharmaceuticals
Arizona University
Arno
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas Pharma
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO Pharmaceuticals
Barr Laboratories
Bayer Healthcare
Baylor College of Medicine
Biogen Idec
BioInvent
Bionovo
Biotech Research & Innovation Centre [Copenhagen, Denmark]
Biotest
BioWa
BiPar Sciences (a subsidiary of Sanofi)
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
British Biotech
BTG
Canadian National Research Council
Cancer Research Technology
Cancer Research UK
Cancer Science Institute of Singapore (CSI Singapore)
Celanese
Celgene
Cell Therapeutics
Centres for Disease Control and Prevention (US)
Centocor Ortho Biotech
Centocor Research & Development
Cephalon
Cetus Corporation
China's State Food and Drug Administration
Chiron
Choongwae
Cipla
Clavis Pharma
Cleveland Clinic
Columbia University
Compugen
Concordia Pharmaceuticals
Constellation Pharmaceuticals
Cougar Biotechnology
Crinos
CTI Technologies
CuraGen
CureVac
Cyclacel Pharmaceuticals
CyDex
Cylene
Cytogen
Cytokinetics
CytRx
Daiichi Sankyo
Dako
Dana Farber Cancer Institute
Dendreon
Dr. Reddy's Laboratories
Eisai
Elan
Elara Pharmaceuticals
Eleison Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
EpiTherapeutics
Epizyme
European Medicines Agency (EMEA/EMA)
European Molecular Biology Laboratory (EMBL)
EUSA Pharma (formerly Cytogen)
Exelixis
Facet Biotech
Food and Drug Administration (US FDA)
Fresenius Kabi
Genentech (now part of Roche)
Generex Biotechnology
Genmab
Genta
Genzyme
Geron
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals
GlycoGenesys
GlycoMimetics
GPC Biotech
Greenwich Therapeutics
GTC Biotherapeutics
Handok
Harvard University
Hospira
Human Genome Sciences
IkerChem
ILEX Oncology
ImClone Systems (a subsidiary of Eli Lilly)
Immune System Therapeutics
ImmunoGen
Incyte
Infinity Pharmaceuticals
Innate Pharma
Intas Biopharmaceuticals
Intellikine
International Cancer Genome Consortium
International Myeloma Working Group
Introgen Therapeutics
Isis Pharmaceuticals
Italfarmaco
Janssen-Cilag
Johnson & Johnson (J&J)
Kadmon Pharmaceuticals
Kaken
Karyopharm Therapeutics
Keryx Biopharmaceuticals
Keyaku Zentaris
Kosan Biosciences
KTB Tumorforschungs
Kyowa Hakko Kirin
Les Laboratoires Servier
Leuchemix
Leukaemia and Lymphoma Society
Ligand
Lipomed
Lonza
Mannkind
Marlborough Research and Development
Marshall Edwards
MD Anderson Cancer Center
MedImmune
Medivation
Merck & Co.
Merck KGaA
Merck Serono (part of Merck KGaA)
MethylGene
Micromet
Millennium Pharmaceuticals (now part of Takeda)
MorphoSys
Mount Sinai Medical Center [US]
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan Pharmaceuticals
Natco Pharma
National Cancer Institute (NCI) [US]
National Cancer Institute (US)
National Health Service (NHS) [UK]
National Institute for Clinical Excellence (NICE) [UK]
National University Cancer Institute Singapore (NCIS)
NCIC Clinical Trials Group
Nektar Therapeutics
Nereus
Nerviano Medical Sciences
Nippon Shinyaku
Novartis
Novo Nordisk
Novogen
Ohio State University
OncoGenex Pharmaceuticals
Onconova
Oncova
Ono Pharmaceuticals
Onyx Pharmaceuticals
Ortho Biotech
OSI Pharmaceuticals
Otsuka
Oxford University
Par Pharmaceutical
PDL BioPharma
Pfizer
PharmaCenter Basel
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia
Pharmacopeia
Pharmacyclics
PharmaMar
Pharmion
Pierre Fabre Pharmaceuticals
Pipex
Piramal Life Sciences
PIramed
PolaRx Biopharmaceuticals
Poniard Pharmaceuticals
Proacta
Progenra
Prospect Therapeutics
Protein Design
Proteolix
R&R
Radient Pharmaceuticals
Regeneron
Rigel
Roche
Rockefeller University
Roxane Laboratories
S*BIO
Salk Institute for Biological Studies
Sandoz (part of Novartis)
Sanofi (sanofi-aventis)
Scancell
Schering-Plough
Scripps Institution of Oceanography
Seattle Genetics
Semafore
Senesco
Shire
Sigma-Tau
Signal Pharmaceuticals
Sirton
Sloan-Kettering Institute
Spectrum Pharmaceuticals
Stada Arzneimittel
Sun Pharmaceuticals
Sunesis
Syndax Pharmaceuticals
Synta Pharmaceuticals
Taiho Pharma
Takeda
Tapestry Pharmaceuticals
TargeGen
Telik
Teva Pharmaceutical Industries
Texas A&M University
The NCIC Clinical Trials Group (Canada)
Threshold Pharmaceuticals
TMRC
Toko
TopoTarget
Tragara
Tufts University
University of Basel PharmaCenter (PharmaCenter Basel)
University of Cambridge
University of Kentucky College of Pharmacy
University of Michigan
University of San Diego
US National Cancer Institute
US National Comprehensive Cancer Network
Vernalis
VioQuest
Wayne State University
WILEX
World Health Organization (WHO)
Wyeth
Xencor
XOMA
XTL Biopharmaceuticals
Yakult Honsha
Yeda Research and Development Company
YM Biosciences
Zelos
Zeltia
Zenyaku Kogyo
Zeria
Ziopharm 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100